$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

$pvct Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040856 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$121.1K	$69.73K	$314.9K
YoY Change	-26.53%	-77.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$225.4K	$360.0K	$334.0K
YoY Change	-27.18%	7.77%	8.88%
% of Gross Profit
Research & Development	$414.1K	$350.8K	$580.4K
YoY Change	29.63%	-39.56%	-4.3%
% of Gross Profit
Depreciation & Amortization	-$1.080K	$10.00K	$2.820K
YoY Change	-152.94%	254.61%	-12.42%
% of Gross Profit
Operating Expenses	$641.7K	$783.9K	$981.1K
YoY Change	1.7%	-20.1%	7.05%
Operating Profit		-$714.1K	-$666.2K
YoY Change		7.2%	-36.39%
Interest Expense	-$34.40K	-$60.00K	-$46.44K
YoY Change	-29.04%	29.2%	1204.49%
% of Operating Profit
Other Income/Expense, Net	-$100.00	-$61.69K	-$47.08K
YoY Change	-85.07%	31.04%	9130.98%
Pretax Income	-$663.4K	-$780.0K	-$713.3K
YoY Change	-9.45%	9.36%	-32.15%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$663.4K	-$775.8K	-$713.3K
YoY Change	-9.45%	8.77%	-32.15%
Net Earnings / Revenue	-547.77%	-1112.59%	-226.51%
Basic Earnings Per Share		$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	-$1.700K
COMMON SHARES
Basic Shares Outstanding	419.5M shares	419.5M shares	419.5M shares
Diluted Shares Outstanding		419.5M shares	419.5M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$76.58K	$370.0K	$67.03K
YoY Change	254.37%	451.99%	-73.62%
Cash & Equivalents	$76.58K	$367.3K	$67.03K
Short-Term Investments
Other Short-Term Assets	$1.288M	$1.220M	$1.832M
YoY Change	-31.4%	-33.4%	629.49%
Inventory
Prepaid Expenses			$187.5K
Receivables
Other Receivables
Total Short-Term Assets	$1.365M	$1.592M	$1.899M
YoY Change	-28.14%	-16.17%	274.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.02K	$14.25K	$22.98K
YoY Change	-42.6%	-37.99%	-75.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$84.05K	$97.76K	$151.0K
YoY Change	-39.13%	-35.28%	61.04%
TOTAL ASSETS
Total Short-Term Assets	$1.365M	$1.592M	$1.899M
Total Long-Term Assets	$84.05K	$97.76K	$151.0K
Total Assets	$1.449M	$1.690M	$2.050M
YoY Change	-28.88%	-17.57%	241.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.676M	$1.785M	$1.941M
YoY Change	-19.98%	-8.04%	54.12%
Accrued Expenses	$3.435M	$3.240M	$2.615M
YoY Change	36.29%	23.91%	39.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$710.0K
YoY Change		-100.0%	255.0%
Long-Term Debt Due	$2.953M	$3.070M	$1.882M
YoY Change	42.86%	63.11%	2652.07%
Total Short-Term Liabilities	$9.017M	$9.172M	$8.824M
YoY Change	10.06%	3.94%	148.63%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$25.30K	$40.00K	$85.02K
YoY Change	-65.52%	-52.95%
Total Long-Term Liabilities	$25.30K	$40.00K	$85.02K
YoY Change	-65.52%	-52.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.017M	$9.172M	$8.824M
Total Long-Term Liabilities	$25.30K	$40.00K	$85.02K
Total Liabilities	$9.042M	$9.209M	$8.909M
YoY Change	9.39%	3.37%	151.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$252.7M	-$252.0M	-$248.9M
YoY Change	1.24%	1.27%
Common Stock	$419.5K	$419.5K	$419.5K
YoY Change	0.01%	0.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.593M	-$7.519M	-$6.859M
YoY Change
Total Liabilities & Shareholders Equity	$1.449M	$1.690M	$2.050M
YoY Change	-28.88%	-17.57%	241.55%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$663.4K	-$775.8K	-$713.3K
YoY Change	-9.45%	8.77%	-32.15%
Depreciation, Depletion And Amortization	-$1.080K	$10.00K	$2.820K
YoY Change	-152.94%	254.61%	-12.42%
Cash From Operating Activities	-$562.0K	-$770.0K	-$816.6K
YoY Change	-25.54%	-5.7%	11.82%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	201.6K	820.0K	496.9K
YoY Change	-57.49%	65.04%	-47.03%
NET CHANGE
Cash From Operating Activities	-562.0K	-770.0K	-816.6K
Cash From Investing Activities
Cash From Financing Activities	201.6K	820.0K	496.9K
Net Change In Cash	-360.4K	50.00K	-319.7K
YoY Change	28.43%	-115.64%	-253.96%
FREE CASH FLOW
Cash From Operating Activities	-$562.0K	-$770.0K	-$816.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000315545
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	PVCT	Rightofuse Asset For Lease Liability RightofuseAssetForLeaseLiability		usd
	PVCT	Conversion Of Notes And Related Accrued Interest ConversionOfNotesAndRelatedAccruedInterest		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	PVCT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36457
	dei	Entity Registrant Name EntityRegistrantName	PROVECTUS BIOPHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0031917
	dei	Entity Address Address Line1 EntityAddressAddressLine1	800 S. Gay Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1610
	dei	Entity Address City Or Town EntityAddressCityOrTown	Knoxville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37929
	dei	City Area Code CityAreaCode	866
	dei	Local Phone Number LocalPhoneNumber	594-5999
	dei	Entity Information Former Legal Or Registered Name EntityInformationFormerLegalOrRegisteredName	Not Applicable
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	419522119	shares
CY2023Q3	us-gaap	Cash Cash	367250	usd
CY2022Q4	us-gaap	Cash Cash	21605	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1042957	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1410102	usd
CY2023Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	947	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	394	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	181180	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	467081	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1592334	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1899182	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	108764	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	102073	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14250	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20941	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	83509	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117123	usd
CY2023Q3	us-gaap	Assets Assets	1690093	usd
CY2022Q4	us-gaap	Assets Assets	2037246	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1785322	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2094258	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1074358	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1510958	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3057678	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2404012	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	13867	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	30844	usd
CY2023Q3	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	122646	usd
CY2022Q4	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	40992	usd
CY2023Q3	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	78066	usd
CY2022Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	239394	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	775000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	625000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	47146	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	44422	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9171583	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8192380	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	37714	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	73376	usd
CY2023Q3	us-gaap	Liabilities Liabilities	9209297	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8265756	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	419522119	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419522119	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	419497119	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419497119	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	419522	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	419497	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	244101958	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	242954193	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-36207	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-35679	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-252026996	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-249588641	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-7519204	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6228510	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1690093	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2037246	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69733	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	314890	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	436600	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	824205	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	350792	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	580390	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1333399	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2068154	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	433089	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	400689	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1399765	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1500278	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	783881	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	981079	usd
	us-gaap	Operating Expenses OperatingExpenses	2733164	usd
	us-gaap	Operating Expenses OperatingExpenses	3568432	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-714148	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-666189	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2296564	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2744227	usd
CY2023Q3	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-167	usd
CY2022Q3	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-638	usd
	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	15798	usd
	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	37621	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-61524	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-46440	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-157589	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-115424	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-61691	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-47078	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-141791	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77803	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-775839	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-713267	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2438355	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2822030	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419515869	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	419515869	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419489239	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	419489239	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419503438	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	419503438	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419461313	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	419461313	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-775839	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-713267	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2438355	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2822030	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1241	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-441	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-2285	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-775839	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-714508	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2438796	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2824315	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6228510	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	54010	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-827454	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	191	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-7001763	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	540222	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-835062	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-278	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-7296881	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2850	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	351232	usd
CY2023Q3	PVCT	Stock Issued During Period Value Conversion Of Series D One Preferred Stock StockIssuedDuringPeriodValueConversionOfSeriesDOnePreferredStock	199875	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-775839	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-441	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-7519204	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187280	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	150000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1030922	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-716	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-5068918	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1077841	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-328	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6147087	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6147087	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3025	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-713267	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1241	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-6858570	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-6858570	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2438355	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2822030	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2850	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3025	usd
	PVCT	Noncash Lease Expense NoncashLeaseExpense	33613	usd
	PVCT	Noncash Lease Expense NoncashLeaseExpense	41947	usd
	us-gaap	Depreciation Depreciation	6691	usd
	us-gaap	Depreciation Depreciation	8857	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	553	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-4351	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-359572	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-142129	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-308728	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	654017	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-436600	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-824205	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	653664	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	442355	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-32938	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-47664	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	150017	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	110536	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2010767	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2286682	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	700000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	550000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1525000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	510000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	234997	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	166317	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1990003	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	893683	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-736	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2592	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21500	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1395591	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1431707	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3106942	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1410207	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1711351	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	367250	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67030	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	1042957	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	1644321	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1410207	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1711351	usd
	us-gaap	Stock Issued1 StockIssued1	150000	usd
	PVCT	Rightofuse Asset For Lease Liability RightofuseAssetForLeaseLiability	130422	usd
	PVCT	Conversion Of Notes And Related Accrued Interest ConversionOfNotesAndRelatedAccruedInterest	804533	usd
	PVCT	Conversion Of2022 Notes And Related Accrued Interest To Series D1 Preferred Stock ConversionOf2022NotesAndRelatedAccruedInterestToSeriesD1PreferredStock	170126	usd
	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-73669	usd
	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-57146	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_806_eus-gaap--NatureOfOperations_zFHPDKWdpaF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82B_zcK3lqnEV76d">Business Organization, Nature of Operations and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (“HXs”). Our lead HX molecule is named rose bengal sodium (“RBS”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of our current clinical development programs and the preclinical formulations of our current drug discovery programs. Importantly, our pharmaceutical-grade RBS displays different therapeutic effects at different concentrations and can be formulated for delivery by different routes of administration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that RBS targets disease in a bifunctional manner. First, direct contact may lead to cell death or repair, depending on the disease being treated and the concentration of the RBS utilized in the treatment. Second, multivariate immune signaling, activation, and response may follow that may manifest as stimulatory, inhibitory, or both.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is the first entity to advance an RBS formulation into clinical trials for the treatment of a disease, such as those trials reported on the clinical trials registry at ClinicalTrials.gov.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is the first and only entity to date to make pharmaceutical-grade RBS successfully, reproducibly, and consistently at a purity of nearly 100%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s small molecule HX medical science platform comprises several different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; <i>in vivo</i> proof-of-concept programs in oncology, hematology, wound healing, and animal health; and <i>in vitro</i> drug discovery programs in infectious diseases and tissue regeneration and repair.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks and Uncertainties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis of Presentation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2022 filed with the SEC on March 30, 2023. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1410207	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	1042957	usd
CY2023Q3	PVCT	Working Capital Deficit WorkingCapitalDeficit	7579249	usd
CY2022Q4	PVCT	Working Capital Deficit WorkingCapitalDeficit	6293198	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2438355	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2822030	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2010767	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2286682	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zxDnqcOcBFL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zSv72X0e0WDg">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities, and the valuation allowance related to the Company’s deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1042957	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zDOSTRQJOSZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zaeEJe1Zijd9">Cash Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zZdDpIWM3ske" title="Insured limits">250,000</span>, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although there can be no assurance that it will not experience any losses in the future. As of September 30, 2023 and December 31, 2022, the Company had cash and restricted cash balances in excess of FDIC insurance limits of $<span id="xdx_90D_eus-gaap--FDICIndemnificationAsset_iI_c20230930_ztWLmClQYDn7" title="Cash in excess FDIC insured amount">1,160,207</span> and $<span id="xdx_908_eus-gaap--FDICIndemnificationAsset_iI_c20221231_z4KBk1Qis5c7" title="Cash in excess FDIC insured amount">1,181,707</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q3	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	1160207	usd
CY2022Q4	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	1181707	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	128636885	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	118243675	shares
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	611646	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	314160	usd
CY2023Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	88691	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	69077	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2234339	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1945589	usd
CY2023Q3	PVCT	Accrued Other Expenses AccruedOtherExpenses	123002	usd
CY2022Q4	PVCT	Accrued Other Expenses AccruedOtherExpenses	75186	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3057678	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2404012	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	78066	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	239394	usd
CY2023Q3	us-gaap	Officers Compensation OfficersCompensation	96250	usd
CY2022Q3	us-gaap	Officers Compensation OfficersCompensation	96250	usd
	us-gaap	Officers Compensation OfficersCompensation	288750	usd
	us-gaap	Officers Compensation OfficersCompensation	288750	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2234339	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1945589	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3425000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	200000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.67
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3225000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.27
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y1M9D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	475000	shares
CY2022Q4	PVCT	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	0.97
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	37500	shares
	PVCT	Weighted Average Exercise Price Forfeited WeightedAverageExercisePriceForfeited	0.29
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	437500	shares
CY2023Q3	PVCT	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	1.03
	PVCT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y7M6D
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	314890	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	824205	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	32938	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	50784	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	130422	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	12497	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	50663	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	25668	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	88828	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3968	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	84860	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	47146	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	37714	usd
CY2021Q4	PVCT	Proceeds From Grant Award For Study Of Animal Cancer And Dermatological ProceedsFromGrantAwardForStudyOfAnimalCancerAndDermatological	2500000	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1074358	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1510958	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69733	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	436600	usd
	PVCT	License Transaction Description LicenseTransactionDescription	The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company (i) paid $5,000 for the option to obtain an exclusive worldwide, royalty-bearing license that had an option expiration date of May 31, 2023, (ii) agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option, (iii) agreed to pay up to $25,000 of past UM patent expenses for this IP, and (iv) entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis

Files In Submission

Name	View Source	Status
pvct-20230930_cal.xml	Edgar Link	unprocessable
0001493152-23-040856-index-headers.html	Edgar Link	pending
0001493152-23-040856-index.html	Edgar Link	pending
0001493152-23-040856.txt	Edgar Link	pending
0001493152-23-040856-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pvct-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pvct-20230930_def.xml	Edgar Link	unprocessable
pvct-20230930_lab.xml	Edgar Link	unprocessable
pvct-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2023 Q4 Form 10-Q Financial Statement

#000149315223040856 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2023 Q4 Form 10-Q Financial Statement

#000149315223040856 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct